IPilogue

DECEMBER 3, 2021

As part of the course requirements, students were asked to write a blog on a topic of their choice. in Hospira Healthcare v Kennedy Trust admitted that the jurisprudence on this matter “is not entirely consistent” (also see Manson J’s comment at para 195 of Hoffman La Roche ). However, the scope of the prohibition is less agreeable.

Intellectual Property Law 106

Intellectual Property Law Patent Infringement Intellectual Property Law 106

LexBlog IP

SEPTEMBER 9, 2022

Director Vidal highlights four different topics as they relate to the duty of disclosure standard: 1. Hospira, Inc. .’’ Accordingly, this notice is meant to address the duty of disclosure and the duty of reasonable inquiry as it relates to the material submitted or received from other governmental agencies.

Government 52

Government Intellectual Property Marketing Marketing 52

43(B)log

AUGUST 9, 2021

5, 2021) Scilex sells an FDA-approved, prescription-strength topical analgesic self-adhesive patch, ZTlido (lidocaine), which is allegedly often prescribed off-label, including for general neuropathic pain (e.g., Hospira, Inc., Scilex Pharmaceuticals Inc. Sanofi-Aventis U.S. LLC, 2021 WL 3417590, F.Supp.3d 3d -, 2021 WL 3417590, No.

False Advertising 59

False Advertising Advertising Advertising Marketing 59

Fish & Richardson Trademark & Copyright Thoughts

JANUARY 11, 2022

Nivestym ® (Pfizer/ Hospira). Retacrit ® (Pfizer/Hospira). The letter discusses the BPCIA and the Hatch-Waxman Act frameworks (for small molecule drugs) and sets forth several topics for USPTO’s consideration and further discussion: engagement between FDA and USPTO to increase efficiencies, possible misuse of the patent system (e.g.,

Litigation 52

Litigation Settlement Patent Marketing 52